Products & Services · Cost of Sales

Royalty — Cost of Sales

Vertex Pharmaceuticals Royalty — Cost of Sales decreased by 15.5% to $232.60M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 0.1%, from $232.40M to $232.60M. Over 3 years (FY 2022 to FY 2025), Royalty — Cost of Sales shows an upward trend with a 8.6% CAGR.

Analysis

StatementSegment
First reportedQ1 2022
Last reportedQ1 2026May 5, 2026
Rolls up toTotal Cost of Revenue
Metric ID: vrtx_segment_royalty_cost_of_sales

Historical Data

17 periods
 Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Value$204.95M$204.95M$204.95M$204.95M$228.25M$228.25M$228.25M$228.25M$233.80M$248.40M$261.00M$271.00M$232.40M$267.00M$275.20M$275.20M$232.60M
QoQ Change—+0.0%+0.0%+0.0%+11.4%+0.0%+0.0%+0.0%+2.4%+6.2%+5.1%+3.8%-14.2%+14.9%+3.1%+0.0%-15.5%
YoY Change————+11.4%+11.4%+11.4%+11.4%+2.4%+8.8%+14.3%+18.7%-0.6%+7.5%+5.4%+1.5%+0.1%
Range$204.95M – $275.20M
CAGR+3.2%
Avg YoY Growth+8.0%
Median YoY Growth+8.8%

Frequently Asked Questions

What is Vertex Pharmaceuticals's royalty — cost of sales?
Vertex Pharmaceuticals (VRTX) reported royalty — cost of sales of $232.60M in Q1 2026.
How has Vertex Pharmaceuticals's royalty — cost of sales changed year-over-year?
Vertex Pharmaceuticals's royalty — cost of sales increased by 0.1% year-over-year, from $232.40M to $232.60M.
What is the long-term trend for Vertex Pharmaceuticals's royalty — cost of sales?
Over 3 years (2022 to 2025), Vertex Pharmaceuticals's royalty — cost of sales has grown at a 8.6% compound annual growth rate (CAGR), from $819.80M to $1.05B.